Caliway Biopharmaceuticals announced that the United States Food and Drug Administration has accepted the CBL-514 Investigational New Drug application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.
Caliway Biopharmaceuticals announced that the United States Food and Drug Administration has accepted the CBL-514 Investigational New Drug application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.